Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

Antimicrob Agents Chemother. 2018 Oct 24;62(11):e00948-18. doi: 10.1128/AAC.00948-18. Print 2018 Nov.

Abstract

We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant. In control animals and those that received cefepime or zidebactam alone, the mean bacterial growth at 24 h was >2 log10 CFU/lung compared with 0-h controls (6.32 ± 0.33 log10 CFU/lung). WCK 5222 produced a decline in the bacterial burden for all isolates (mean reduction, -3.34 ± 0.85 log10 CFU/lung) and demonstrated remarkable potency.

Keywords: Acinetobacter; carbapenem resistant; lung infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter baumannii / drug effects*
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Azabicyclo Compounds / pharmacology*
  • Carbapenems / pharmacology*
  • Cefepime / pharmacology*
  • Cephalosporins / pharmacology*
  • Cyclooctanes / pharmacology*
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Female
  • Lung / microbiology
  • Lung Diseases / drug therapy*
  • Lung Diseases / microbiology
  • Mice
  • Mice, Inbred ICR
  • Microbial Sensitivity Tests / methods
  • Piperidines / pharmacology*
  • beta-Lactamase Inhibitors / pharmacology

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Carbapenems
  • Cephalosporins
  • Cyclooctanes
  • Piperidines
  • WCK 5222
  • beta-Lactamase Inhibitors
  • zidebactam
  • Cefepime